HYTN Announces Arrangement Agreement to Facilitate the Spin-Out of a Peptide-Focused Drug Development Business
VANCOUVER, British Columbia, Sept. 02, 2026 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC Pink: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, announces that it has entered into an arrangement agreement with Peptide Development Labs Inc. (“PDL”) dated September 1, 2026 (the…
HYTN Innovations Inc., a Canadian pharmaceutical company focused on psychoactive and psychotropic products, has announced an arrangement agreement with Peptide Development Labs Inc. The agreement, signed on September 1, 2026, will result in the separation of HYTN's peptide-focused drug development business, which is focused on pre-clinical development of a subcutaneous injectable BPC-157 drug candidate for treating refractory ligament disorders.
The arrangement will see HYTN shareholders receive common shares in Peptide Development Labs, known as PDL, in proportion to their original shareholdings in HYTN. Currently, HYTN holds around 17% of PDL, and following a concurrent financing, shareholders are anticipated to own approximately 14% of PDL. This decision was unanimously approved by HYTN's Board of Directors after a special committee had recommended the Arrangement.
Written by urgent.news from Financial Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
